Novartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran for primary prevention of cardiovascular disease. Health Secretary Matt Hancock ...

Homozygous familial hypercholesterolaemia affects approximately 30 000 individuals worldwide.1,2 Patients have untreated high ...

Novartis is heading the pack with Leqvio (inclisiran), its PCSK9-targeting antisense drug for reducing cholesterol levels in the blood, but is being pursued by a competing drug from AstraZeneca ...